Form 4: Coeptis CFO Boosts Stake, Exchanges Underwater Options

Coeptis Therapeutics CFO Brian Cogley acquired 22,500 shares through option exercise and a restricted stock grant via an option exchange program.

Summary

• Coeptis Therapeutics Holdings, Inc. (COEP) Chief Financial Officer, Brian Cogley, reported changes in his beneficial ownership.
• On February 11, 2026, Mr. Cogley exercised stock options to purchase 10,000 shares of common stock at an exercise price of $10.56 per share.
• On the same date, Mr. Cogley received a grant of 12,500 restricted shares of common stock at a price of $0.
• This restricted stock grant was part of an option exchange program where Mr. Cogley surrendered previously held 'underwater options'.
• Following these transactions, Mr. Cogley directly beneficially owns a total of 22,500 shares of Coeptis Therapeutics Holdings, Inc. common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development. While the option exchange reflects past underperformance, the re-incentivization of the CFO and his direct share acquisition signal renewed alignment with shareholder interests and potential confidence in future growth.

Positives

• The exercise of stock options by the CFO to acquire 10,000 shares at $10.56 indicates management's confidence in the company's current valuation or future prospects.
• The grant of restricted stock through an option exchange program re-aligns management incentives with future stock price appreciation, as the CFO now holds new equity with direct upside potential.

Negatives

• The option exchange program, where 'underwater options' were surrendered, suggests that the company's stock price had previously underperformed, rendering the original options worthless and necessitating a re-incentivization strategy.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance, but the re-incentivization of the CFO through an option exchange program implies a strategic effort to motivate management for future performance.

Industry Context

StockSavvy.ai notes that option exchange programs are a common mechanism in the biotechnology and pharmaceutical sectors, particularly for companies experiencing stock price volatility or underperformance, to retain and motivate key executives by resetting equity incentives. This move by Coeptis Therapeutics aligns with broader industry practices aimed at ensuring management's long-term commitment.

Comparison to Industry Standards

• Option exchange programs are a recognized tool for executive retention and motivation, especially in industries like biotech where R&D cycles are long and stock performance can be volatile. Companies such as Moderna (MRNA) and BioNTech (BNTX) have utilized various equity compensation strategies to align executive interests with long-term shareholder value, though specific option exchange details vary.
• The grant of restricted stock at a $0 exercise price is standard for such grants, often tied to vesting schedules, which is a common practice across publicly traded companies to incentivize future performance and retention.

Related Party Transactions

• The option exchange program, involving the surrender of underwater options for a grant of restricted stock, constitutes a related party transaction between the company and its Chief Financial Officer, Brian Cogley, as part of his compensation.

Stakeholder Impact

• Shareholders: The re-incentivization of the CFO could lead to improved management focus on long-term value creation, potentially benefiting shareholders. However, the issuance of new restricted stock could lead to minor dilution.
• Employees: The option exchange program for a key executive might signal a broader strategy for employee retention and motivation, especially if similar programs are extended to other employees.
• Management: The CFO directly benefits from new equity incentives, aligning his financial interests more closely with the company's stock performance.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions and executive compensation adjustments. While the re-incentivization of the CFO is a positive for management alignment, it does not present new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. The option exchange program, while beneficial for the executive, also implicitly acknowledges past stock underperformance. Therefore, a 'hold' recommendation is appropriate as investors await more substantive operational or financial updates.

Keywords

Coeptis Therapeutics, COEP, Form 4, Insider Trading, Stock Options, Restricted Stock, Option Exchange, CFO, Beneficial Ownership